Acquired resistance after treatment for non-small cell lung cancer (NSCLC) with third- generation EGFR tyrosine kinase inhibitors (TKI) was associated with diverse pathways, according to a recent study published in Cancer.
Moreover, the treatment with osimertinib was associated with loss of EGFR T790M and emergence of EGFR-independent resistance mechanisms.
“Our data reveal the unique characteristic of resistance mechanisms acquired after treatment with third-generation EGFR TKIs in patients who have advanced NSCLC harboring the EGFR T790M mutation,” wrote the researchers.
In the population, there were 36 patients with posttreatment biopsies, of which EGFR-dependent mechanisms were observed in 10 patients (5 in the osimertinib group and 5 in the olmutinib group). EGFR-independent mechanisms were found in 21 patients (11 in the osimertinib group and 10 in the olmutinib…